Literature DB >> 18641538

Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction.

Aurélie Fayet1, Alexandre Béguin, Begona Martinez de Tejada, Sara Colombo, Matthias Cavassini, Stefan Gerber, Chin B Eap, Amalio Telenti, Thierry Buclin, Jérôme Biollaz, Laurent A Decosterd.   

Abstract

Total plasma concentrations are used for therapeutic drug monitoring of antiretroviral drugs, whereas antiviral activity is expected to depend on unbound concentrations. The determination of free (unbound) concentrations by ultrafiltration may be flawed by the irreversible adsorption of many drugs onto the membrane filters and plastic components of the device. The authors describe a modified ultrafiltration method enabling the accurate measurement of unbound concentrations of 10 antiretroviral drugs by liquid chromatography-tandem mass spectroscopy, which circumvents the problem of loss by adsorption in the early ultrafiltration fractions. The method was applied to assess the variability of free fractions of antiretroviral drugs during routine therapeutic drug monitoring in 144 patients with HIV. In in vitro experiments, ultrafiltrate collected in four fractions (0-8, 8-16, 16-24, and 24-30 minutes) gave much lower and more variable free drug concentrations in the first ultrafiltrate fraction than in the last three fractions for lopinavir, nelfinavir, saquinavir, tipranavir, and efavirenz. In the last two fractions, free concentrations remained constant, indicating saturable adsorption. The adsorption was modest for indinavir, amprenavir, and ritonavir, and unnoticeable for atazanavir and nevirapine. Free fraction values obtained with this modified ultrafiltration method reveal substantial interindividual variability, suggesting that monitoring unbound antiretroviral drug concentrations may increase its clinical usefulness, especially for lopinavir, saquinavir, and efavirenz.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18641538     DOI: 10.1097/FTD.0b013e3181817318

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  10 in total

1.  Calculation of normalized drug concentrations in the presence of altered plasma protein binding.

Authors:  Florin Marcel Musteata
Journal:  Clin Pharmacokinet       Date:  2012-01-01       Impact factor: 6.447

2.  Free and total plasma concentrations of elvitegravir/cobicistat during pregnancy and postpartum: a case report.

Authors:  Catia Marzolini; Laurent Decosterd; Ursula Winterfeld; Frédéric Tissot; Katyuska Francini; Thierry Buclin; Françoise Livio
Journal:  Br J Clin Pharmacol       Date:  2017-05-16       Impact factor: 4.335

3.  Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours.

Authors:  Amina Haouala; Nicolas Widmer; Monia Guidi; Michael Montemurro; Serge Leyvraz; Thierry Buclin; Chin B Eap; Laurent A Decosterd; Chantal Csajka
Journal:  Br J Clin Pharmacol       Date:  2013-04       Impact factor: 4.335

4.  Combination lopinavir and ritonavir alter exogenous and endogenous bile acid disposition in sandwich-cultured rat hepatocytes.

Authors:  LaToya M Griffin; Paul B Watkins; Cassandra H Perry; Robert L St Claire; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2012-10-22       Impact factor: 3.922

5.  Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets.

Authors:  Louisa Pollock; Laura Else; Goenke Poerksen; Elizabeth Molyneux; Peter Moons; Sarah Walker; William Fraser; David Back; Saye Khoo
Journal:  J Antimicrob Chemother       Date:  2009-10-06       Impact factor: 5.790

6.  A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans.

Authors:  Jackson K Mukonzo; Daniel Röshammar; Paul Waako; Maria Andersson; Takashi Fukasawa; Lili Milani; Jan Olof Svensson; Jasper Ogwal-Okeng; Lars L Gustafsson; Eleni Aklillu
Journal:  Br J Clin Pharmacol       Date:  2009-11       Impact factor: 4.335

7.  Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations.

Authors:  Cecile A Delille; Sarah T Pruett; Vincent C Marconi; Jeffrey L Lennox; Wendy S Armstrong; Richard F Arrendale; Anandi N Sheth; Kirk A Easley; Edward P Acosta; Aswani Vunnava; Ighovwerha Ofotokun
Journal:  J Clin Pharmacol       Date:  2014-04-08       Impact factor: 3.126

8.  Determinants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapy.

Authors:  Tracy R Glass; Margalida Rotger; Amalio Telenti; Laurent Decosterd; Chantal Csajka; Heiner C Bucher; Huldrych F Günthard; Martin Rickenbach; Dunja Nicca; Bernard Hirschel; Enos Bernasconi; Gilles Wandeler; Manuel Battegay; Catia Marzolini
Journal:  PLoS One       Date:  2012-01-03       Impact factor: 3.240

9.  Normalized vitamin D metabolite concentrations are better correlated to pharmacological effects than measured concentrations.

Authors:  Darius Mason; Paul J Donabella; Daryl Nnani; Florin Marcel Musteata
Journal:  Future Sci OA       Date:  2015-11-30

10.  Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapine.

Authors:  Alessandro Schipani; David Back; Andrew Owen; Gerry Davies; Saye Khoo; Marco Siccardi
Journal:  Clin Pharmacokinet       Date:  2015-01       Impact factor: 5.577

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.